Dynamics of course and adherence to treatment in conservative and surgical treatment of chronic coronary artery disease connected with hypertension

The purpose of this study was to compare the clinical status, miocardial morphofunctional parameters and adherence to treatment on the background of optimal drug therapy (ODT, including agents improve the prognosis and percutaneous coronary intervention (PCf) in combination with ODT in patients with stable coronary artery disease in combination with hypertension grade 1-2 during prospective observation. The study included 125 men aged 50-75 years. The main group (PCf with ODT) included 78 patients aged 61.5 ± 8.5 years; the comparison group (ODT includes 47 patients aged 63.5 ± 7.1 years. Patients did not significantly differ in age and frequency of major cardiovascular risk factors. Both groups’ patients also did not significantly differ in the angina functional class, of ischemic and hypertensive history duration, myocardial infarct frequency and HF functional class. After a year of observation, there were no significant differences in myocardium morphometric and functional parameters in both groups patients against the background of the treatment. 64 (51.2 %) patients, 42 in the main group and 22 in the comparison group, remained fully adherent to treatment. Greatest commitment found in patients younger than 60 years. The main reason of low adherence was a lack of understanding of the need medication taking with good health and normal blood pressure (BP)

stable coronary artery disease, arterial hypertension, coronary angiography, echocardiography, PCI with stenting, optimal drug therapy, treatment adherence

1. Antithrombotic Trialist’s Collaboration. Collaborative metaanalysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86

2. Boden WE, O’Rourke RA, Teo KK, et al. The Evolving Pattern of Symptomatic Coronary Artery Disease in the United States and Canada: Baseline Characteristics of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial. Am J Cardiol2007; 99: 208-12.

3. Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARY2D) Study Group. A Randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009; 360: 2503-2515.

4. Kannel W. B., Feinleib M. Natural history of angina pectoris in the Framingham study. Prognosis and survival. Am J Cardiol. 1972; 29: 154-163.

5. Morisky D. E., Green L. W. and Levine D. M. (1986) Concurrent and Predictive Validity of a Self-Reported Measure of Medication Adherence. Medical Care, 24, 67-74.

6. ESC guidelines on the management of stable coronary artery disease. The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. http://eurheartj.oxfordjournals.org/ content/early/2013/ 08/28/eurheartj.eht296.

7. Беленков Ю. Н. Ингибиторы ангиотензии-превращающего фермента в лечение сердечно-сосудистых заболеваний (Квинаприл и эндотелиальная дисфункция) / Ю. Н. Беленков, Ф. Т. Агеев, В. Ю. Мареев.- М.: Москва, 2001. - 86 с.

8. Боголепова А. Н., Семушкина Е. Г. Роль сердечно-сосудистой патологии в формировании и прогрессировании когнитивных нарушений // Неврологический журнал. 2011; 16 (4): 27-31.

9. Громнацкий Н. И. Влияние небиволола на ремоделирование сердца и сосудов и состояние гемодинамики у больных артериальной гипертонией / Н. И. Громнацкий, Н. Б. Дюсьмикеева // Кардиология. 2002.- № 10.- С. 27-30.

10. Здравоохранение в России. 2017: Стат. сб. / Росстат.-М., 2017.- 170 с. Л. И. Агеева, Г. А. Александрова, Н. М. Зайченко, Г. Н. Кириллова, С. А. Леонов, Е. В. Огрызко, И. А. Титова, Т. Л. Харькова, В. Ж. Чумарина, Е. М. Шубочкина. Стр. 31.

11. Мазур Н.А. Оценка эффективности лечения больных хронической ишемической болезнью сердца / Н. А. Мазур // Кардиология. - 2002. № 4.- С. 78-81.